Through the integration of Leukocare’s unique SPS® formulation platform and Rentschler Biopharma’s proven development and manufacturing process, clients gain exciting new opportunities to realize the full potential of their biopharmaceuticals in the market.
Formulation development in the current manufacturing process is suboptimal
- Current standards do not leverage the strategic opportunities of formulation development
- Current standards focus on formulation development of the commercial product much too late in product development
- This can delay development programs if product opportunities are not maximized prior to phase II trials
- Changes of formulations after phase II may require additional studies, costs, and delays of the overall development programs
- Not considering competitor developments and needs of physicians, patients, and payors early enough may result in a less competitive product
The Rentschler Biopharma/Leukocare Alliance
- The Alliance of Rentschler Biopharma and Leukocare offers contract development and manufacturing with proven excellence including best-in-class formulation that enables clients to realize the full medical and commercial potential of their products. Advanced formulation development is considered at every step of the manufacturing process to capitalize on the full product potential.
- The Alliance offers full-service development and manufacturing from gene to vial and full integration of patented SPS® (Stabilizing and Protecting Solutions) formulation technology at every relevant step of development and manufacturing.
- Leukocare is the specialized technology partner and the exclusive formulation developer for Rentschler Biopharma’s biopharmaceuticals business. Rentschler Biopharma is the first and only contract development and manufacturing organization to use Leukocare´s patented SPS® formulation technology.